Is combined estrogen/progestogen hormone therapy worth the risk?

Climacteric

Volumn 6, Issue 3, 2003, Pages 177-179

  Sturdee, David W ^a   MacLennan, Alastair H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORGESTREL; RALOXIFENE;

ADULT; BREAST CANCER; BREAST TUMOR; CANCER RISK; DRUG COMBINATION; EDITORIAL; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HORMONAL THERAPY; HUMAN; IATROGENIC DISEASE; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR;

EID: 0141504408     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.6.3.177.179     Document Type: Editorial

References (10)

1. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
2. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
3. Chlebowski RT, Hendrix SL, Langer RD, et al., for the WHI investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2003;289:3243-53
4. Li CI, Malone KE, Porter PL, Weiss NS, et al. Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. J Am Med Assoc 2003;289:3254-63
5. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy: a review. Climacteric 2000;3:199-211
6. Cauley JA, Norton L, Lippman ME, Eckert S, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Breast Cancer Research Treatment 2001;65:125-34
7. Lundstrom E, Chrislow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-22
8. MacLennan AH. Cancer, cohorts, confounding and consensus (Editorial). Climacteric 1998;1:89-90
9. Lagro-Janssen, Rosser WW, van Weel C. Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces (Editorial). Lancet 2003;362:414-15
10. MacLennnan AH, Sturdee DW. Is hormone therapy still an option for the management of osteoporosis? (Editorial). Climacteric 2003;6:89-91